CMS Proposes Non-Coverage For S&N Exogen For Nonunion Fracture Healing
This article was originally published in The Gray Sheet
Executive Summary
CMS is continuing its recent trend of promoting clinical trial coverage by proposing to extend reimbursement for Smith & Nephew's Exogen ultrasound bone growth stimulator for nonunion fracture healing for recipients enrolled in a qualifying trial
You may also be interested in...
S&N Defies CMS History, Secures Coverage After Negative Proposed Decision
Smith & Nephew's last-ditch effort to supply CMS with pooled data from a PMA study convinced the agency to overturn its proposed national non-coverage decision for ultrasound stimulation for nonunion fracture healing
S&N Defies CMS History, Secures Coverage After Negative Proposed Decision
Smith & Nephew's last-ditch effort to supply CMS with pooled data from a PMA study convinced the agency to overturn its proposed national non-coverage decision for ultrasound stimulation for nonunion fracture healing
Exogen Medicare Coverage Reconsideration Attracts Physician Support
Unrestricted national coverage for Smith & Nephew's Exogen ultrasonic bone growth stimulator is warranted due to potential cost savings, high patient compatibility and shorter treatment times compared to surgery, practitioners and patients tell CMS